Abstract
From emerging specialist manufacturers to established companies seeking new
opportunities, alternative drug delivery technologies are increasingly being
seen as a route to a competitive edge in the generics industry. This new
report from Espicom provides a complete review of the emerging opportunities
and operating environment for inhalation and nasal spray drugs.
Providing…
- Product forecasts by value 2006/2011
- Patent expiry opportunities to 2016
- Generic market context
- Competitive evaluation with 18 company reviews
Exciting opportunities in this high growth area can be expected over the next
10 years. At least nine significant products will lose patent protection in
key markets and this number could increase depending on the outcome of patent
challenges.
The inhalation and intranasal drugs discussed in this report from Espicom had
combined sales exceeding US$18 billion in 2006. These drugs are used in the
treatment of asthma, COPD, allergic rhinitis, influenza, migraine and
osteoporosis, and in general anaesthesia.
In the longer term, novel inhalation and intranasal drug candidates which are
being developed now could greatly expand the therapeutic coverage of these
drug delivery technologies and potentially provide a lucrative future for the
generic industry.
The generics market is undergoing radical restructuring, with much
rationalisation of the corporate landscape. In such a competitive cauldron
companies are now seeking not just new opportunities but opportunities which
combine good profit levels and a degree of product novelty - both of which are
available in the inhalation and nasal spray market.
This new report from Espicom provides a complete review of the emerging
opportunities and operating environment for inhalation and nasal spray drugs.
It reviews products currently available generically and assesses the prospects
for those drugs losing patent protection over the next 10 years. The whole
sector is put in the context of the global generic market and the significant
players are assessed.
Profits through novel delivery
The traditional view of generic drugs is that they offer a cheap alternative
to their branded equivalents. Cost has been an important factor in their
development, particularly for oral drugs that are relatively cheap to produce
and can be introduced to the market at a fraction of the price of the original
drug.
As the generic industry matures, however, companies are increasingly looking
for higher profit margins. From emerging specialist manufacturers to
established companies seeking new opportunities, alternative drug delivery
technologies are increasingly being seen as a route to a competitive edge in
the generics industry. That is why this report focuses on the opportunities
for inhalation and nasal spray generic drugs.
Inhalation and nasal spray drug delivery technologies are not an entirely
unknown concept for generics manufacturers; many have a presence in the
inhalation market, if only with one or two bronchodilators used in the
treatment of asthma and chronic obstructive pulmonary disease (COPD).
Moving forward, however, a greater commitment to development will be required
for success in this market. By the end of 2008, asthma inhalers which use
ozone-depleting chlorofluorocarbon (CFC) propellants will have been entirely
phased-out of the US market. Only those companies that have successfully
developed more ozone-friendly hydrofluoroalkane (HFA) inhalers will be able to
compete for market share.
View Cart
